This is exemplified with the FDA approval of PARP inhibitor olaparib for patients with germline BRCA1 or BRCA2 mutations in platinum-sensitive metastatic PDAC [8], further demonstrating the importance of deciphering the tumours at the molecular level. The gene discussed is BRCA1; the disease is neoplasm.